Inscripta, Inc., developer of the first benchtop platform for scalable Digital Genome Engineering, is proud to announce its participation as the presenting sponsor in the upcoming SynBioBeta 2019 conference. SynBioBeta is the leading industry conference bringing together biological engineers, investors, innovators, and entrepreneurs to build a better world with biology. The meeting will take place October 1-3, 2019, in San Francisco.
Inscripta CEO Kevin Ness, Ph.D., will be kicking off the meeting with a keynote presentation on the first morning of the conference, where Dr. Ness will provide a preview of Inscripta’s automated Digital Genome Engineering platform. Inscripta will also be hosting additional data-packed events: a workshop called “Leveraging the Power of Digital Genome Engineering” at 12:30 p.m. on October 2; and a breakout session entitled “Genome Scale Mapping of Genotype to Phenotype Relationships for Engineering & Discovery” on October 3 at 1:30 p.m.
“We believe that SynBioBeta, with its well-earned reputation for being at the forefront of connecting leaders in biological engineering, is the perfect venue to introduce our benchtop Digital Genome Engineering platform to the scientific community,” said Dr. Ness. “We are excited to be the presenting sponsor and are looking forward to engaging the synthetic biology community. Together we can now explore multiple genome-scale applications with the Inscripta platform that were just not possible before.”
In addition to the keynote address and data workshops, on October 3 Inscripta will sponsor a fireside chat entitled “Genomics 2.0 and Beyond” with Bryan Roberts, Ph.D., healthcare investor and partner at Venrock, and John Stuelpnagel, DVM, Chairman of the Board of Inscripta and 10xGenomics, and co-founder and first CEO of Illumina.
Attendees can also find more information and demonstrations at Inscripta’s booth (#214), and are invited to join us at Inscripta’s Evening Welcome Reception on Oct 1 from 7-9 p.m.
About Inscripta
Inscripta is developing the world’s first benchtop platform for scalable Digital Genome Engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, reagents, and software, will offer a fully automated workflow that enables multiplexed, trackable editing of cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo, with offices also in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. For more information, visit www.inscripta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005288/en/